Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Charles River Labs (CRL) PT Raised to $301 at Credit Suisse
February 17, 2021 4:13 PM ESTCredit Suisse analyst Erin Wilson Wright raised the price target on Charles River Labs (NYSE: CRL) to $301.00 (from $259.00) while maintaining a Neutral rating.
The analyst comments "CRLs 4Q EPS ($2.39) handily exceeded our $2.04 on stronger revenues and profitability. Below the line factors also added $0.15. It... More
Charles River Laboratories (CRL) Tops Q4 EPS by 29c, Revenues Beat; Offers FY21 EPS Guidance Above Consensus
February 17, 2021 7:11 AM ESTCharles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.39, $0.29 better than the analyst estimate of $2.10. Revenue for the quarter came in at $791 million versus the consensus estimate of $756.86 million.
Fourth-Quarter Revenue of $791.0 Million and Full-Year Revenue of $2.92 Billion Fourth-Quarter GAAP Earnings per Share of $2.81 and Non-GAAP Earnings per Share of $2.39 Full-Year GAAP Earnings per Share of $7.20 and Non-GAAP Earnings per Share of $8.13 Announces Definitive Agreement to Acquire Cognate BioServices, A Premier, Cell and Gene Therapy CDMOGUIDANCE:
Charles River Laboratories sees FY2021 EPS of... More
